U.K. Cancer Drug Fund May Shift To ‘Coverage With Evidence Development’-Style Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
Fund would revaluate benefits – and pricing – of drugs it covers, adding extra layer of complexity to accessing new medicines for Britain’s cancer patients.
You may also be interested in...
Emerging Markets Earnings: Strong Showing For Bayer Despite China Nexavar Hiccup
Bayer slowly but surely nears the halfway mark for the proportion of overall sales from emerging markets with double-digit growth in the third quarter, though the company faced some hiccups related to Nexavar stocks in China
Emerging Markets Earnings: Strong Showing For Bayer Despite China Nexavar Hiccup
Bayer slowly but surely nears the halfway mark for the proportion of overall sales from emerging markets with double-digit growth in the third quarter, though the company faced some hiccups related to Nexavar stocks in China
Cohesive Coverage-With-Evidence Authority Needed For Medicare, Lawmakers Told
Former CMS coverage chief Louis Jacques told House lawmakers that the agency’s authority to implement coverage-with-evidence-development policies are fragmented, hindering application of the program.